Literature DB >> 18558087

Cloning of apoB intrabodies: specific knockdown of apoB in HepG2 cells.

Wei Liao1, Randall W Strube, Ross W Milne, Si-Yi Chen, Lawrence Chan.   

Abstract

Apolipoprotein (apo) B is essential for the assembly and secretion of triglyceride-rich lipoproteins made by the liver. As the sole protein component in LDL, apoB is an important determinant of atherosclerosis susceptibility and a potential pharmaceutical target. Single-chain antibodies (sFvs) are the smallest fragment of an IgG molecule capable of maintaining the antigen binding specificity of the parental antibody. In the present study, we describe the cloning and construction of two intracellular antibodies (intrabodies) to human apoB. We targeted these intrabodies to the endoplasmic reticulum for the purpose of retaining nascent apoB within the ER, thereby preventing its secretion. Expression of the 1D1 intrabody in the apoB-secreting human hepatoma cell line HepG2 resulted in marked reduction of apoB secretion. This study demonstrates the utility of an intrabody to specifically block the secretion of a protein determinant of plasma LDL as a therapeutic strategy for the treatment of hyperlipidemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18558087      PMCID: PMC2496960          DOI: 10.1016/j.bbrc.2008.06.020

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  Hammerhead ribozyme as a therapeutic agent for hyperlipidemia: production of truncated apolipoprotein B and hypolipidemic effects in a dyslipidemia murine model.

Authors:  M Enjoji; F Wang; M Nakamuta; L Chan; B B Teng
Journal:  Hum Gene Ther       Date:  2000-11-20       Impact factor: 5.695

2.  Use of bacterial expression cloning to localize the epitopes for a series of monoclonal antibodies against apolipoprotein B100.

Authors:  R J Pease; R W Milne; W K Jessup; A Law; P Provost; J C Fruchart; R T Dean; Y L Marcel; J Scott
Journal:  J Biol Chem       Date:  1990-01-05       Impact factor: 5.157

3.  Well-defined regions of apolipoprotein B-100 undergo conformational change during its intravascular metabolism.

Authors:  X Wang; R Pease; J Bertinato; R W Milne
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-05       Impact factor: 8.311

4.  Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.

Authors:  R Orlandi; D H Güssow; P T Jones; G Winter
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

5.  Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

Authors:  John J P Kastelein; Mark K Wedel; Brenda F Baker; John Su; JoAnn D Bradley; Rosie Z Yu; Emil Chuang; Mark J Graham; Rosanne M Crooke
Journal:  Circulation       Date:  2006-10-09       Impact factor: 29.690

6.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

7.  Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody.

Authors:  W A Marasco; W A Haseltine; S Y Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

8.  Ubiquitin-dependent and -independent proteasomal degradation of apoB associated with endoplasmic reticulum and Golgi apparatus, respectively, in HepG2 cells.

Authors:  Wei Liao; Benny Hung-Junn Chang; Michael Mancini; Lawrence Chan
Journal:  J Cell Biochem       Date:  2003-08-01       Impact factor: 4.429

9.  Intracellular antibodies as a new class of therapeutic molecules for gene therapy.

Authors:  S Y Chen; J Bagley; W A Marasco
Journal:  Hum Gene Ther       Date:  1994-05       Impact factor: 5.695

10.  Proteasome-mediated degradation of apolipoprotein B targets both nascent peptides cotranslationally before translocation and full-length apolipoprotein B after translocation into the endoplasmic reticulum.

Authors:  W Liao; S C Yeung; L Chan
Journal:  J Biol Chem       Date:  1998-10-16       Impact factor: 5.157

View more
  2 in total

1.  Suppression of p75 neurotrophin receptor surface expression with intrabodies influences Bcl-xL mRNA expression and neurite outgrowth in PC12 cells.

Authors:  Congcong Zhang; Saskia Helmsing; Marta Zagrebelsky; Thomas Schirrmann; Andrea L J Marschall; Manuela Schüngel; Martin Korte; Michael Hust; Stefan Dübel
Journal:  PLoS One       Date:  2012-01-24       Impact factor: 3.240

Review 2.  Specific in vivo knockdown of protein function by intrabodies.

Authors:  Andrea L J Marschall; Stefan Dübel; Thomas Böldicke
Journal:  MAbs       Date:  2015-08-07       Impact factor: 5.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.